An update on PARP inhibitors—moving to the adjuvant setting
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/nrclinonc.2014.163.pdf
Reference101 articles.
1. Amé, J.-C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882–893 (2004).
2. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
3. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
4. Metzger-Filho, O. et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 30, 1879–1887 (2012).
5. Anders, C. K. et al. Poly(ADP-ribose) polymerase inhibition: 'targeted' therapy for triple-negative breast cancer. Clin. Cancer Res. 16, 4702–4710 (2010).
Cited by 311 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM;Nature Communications;2024-08-14
2. Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients;Gynecologic Oncology;2024-08
3. PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer;Genes & Immunity;2024-06-12
4. Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review;Current Cancer Drug Targets;2024-04-02
5. Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects;Investigational New Drugs;2023-12-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3